- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Prostate cancer
- Meeting Date: March 2024
- Public Summary Document (PSD) March 2024 PBAC Meeting - (PDF 1.9MB)
- Public Summary Document (PSD) March 2024 PBAC Meeting - (Word 2MB)
Talazoparib – March 2024
Talazoparib: Capsule 0.1 mg, Capsule 0.25 mg, Capsule 0.35 mg, Capsule 0.5 mg; Talzenna®
Last updated
30 May 2025